Fundraising Fox

Versantis

Acquired

2 known investors

GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias. Its pipeline spans eight R&D programs plus a diagnostic franchise for NASH/MASH and ammonia, and it discovered elafibranor, now approved and marketed as Iqirvo for primary biliary cholangitis.

BiotechDigital HealthMedical Devices

Investors · 2

OCCIDENTMunich
Verve VenturesZug · $1.1M – $2.2M

In the news

Versantis revisits investors for $16.2m -globalventuring.com · Sep 2019Versantis raises CHF16m in Series B financing - European Biotechnology Magazineeuropean-biotechnology.com · Sep 2019Versantis raises cash to take liver failure drug to clinical POC | Fierce Biotechfiercebiotech.com · Sep 2019Versantis raises funds to advance liver disease drugspharmaceutical-technology.com · Sep 2019Versantis Raises $16.1 Million to Develop Treatment for Liver Disease Including ACLF - Global Genesglobalgenes.org · Sep 2019Versantis Raises CHF4.4M in Series A Funding Round - FinSMEsfinsmes.com · Mar 2017

Frequently asked questions

What does Versantis do?
GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias. Its pipeline spans eight R&D programs plus a diagnostic franchise for NASH/MASH and ammonia, and it discovered elafibranor, now approved and marketed as Iqirvo for primary biliary cholangitis.
Who are Versantis's investors?
Versantis's investors include OCCIDENT, Verve Ventures.